According to a market report, published by Sheer Analytics and Insights, the global regenerative medicine market was valued at $28.9 billion in 2021 and it is expected to reach $78.1 billion at a CAGR of 8.8% between 2022 and 2032. Over the past few decades, there has been a major global increase in the incidence and prevalence of chronic diseases like cardiovascular disease (CVD), cancer, diabetes, ulcers, and genetic disorders like cystic fibrosis. Diabetes and obesity can contribute to an increased prevalence and complexity of wounds, including infections, ulcerations (leg or foot ulcers), and surgical wounds, which will necessitate expensive medical care. Additionally, it is projected that developments in cell biology, genomics research, and gene-editing technologies would support the industry's expansion. Clinical trials for stem cell-based regenerative therapies are now being conducted. These treatments have the potential to repair damaged specialized cells in a variety of deadly illnesses, including cancer, Alzheimer's, neurodegenerative diseases, and spinal cord injuries. Furthermore, the development of gene-based treatment, which employs targeted delivery of DNA as a drug to combat numerous illnesses, is a result of ongoing developments in molecular medicine. The loss of organs and tissues as a result of illness or organ damage has sparked research into drugs that can regenerate tissues and lessen the need for transplantation. These primary factors are driving the regenerative medicine market during the forecast period.
The number of senior citizens is rising quickly. The number is anticipated to increase in developing nations including South Korea, China, Japan, and India. One of the many health problems that the elderly population deals with is cancer. Other problems include diabetes, high blood pressure, and blood sugar levels. They should take better care of their health. They consequently need to take drugs regularly. As a result, the market for regenerative medicine will expand during the forecasted period due to the rising elderly population. These major factors are estimated to accelerate market growth during the forecast period.
Request a free PDF sample report: https://www.sheeranalyticsandinsights.com/request-sample/regenerative-medicine-market-21
Normal cells undergo a multi-stage process that often starts with a precancerous lesion and proceeds to a malignant tumor before becoming tumor cells, which is how cancer is brought on. The interaction of a person's inherited elements results in these alterations. Surgery, radiation, and chemotherapy are frequently used to treat cancer. Because hematopoietic stem or more developed cells naturally have the potential to target and eradicate disease cells, cancer immunotherapy employing regenerative medicine has the advantage of being able to do so. These would create more growth opportunities for the market in the future.
Cell and gene therapies, which are a huge achievement in science and medicine, are required for patients with terminal illnesses and serious disorders. These treatments are altering how illnesses are managed and perhaps even healed. Additionally, such treatments will soon allow doctors and other medical professionals to inject genes or cells into patients in place of several medications and operations. For marketing and sales, regenerative medicine products need Food and Drug Administration (FDA) licenses or approvals. The government's strict rules are thus the largest obstacle to the market's expansion.
Some new developments in the global regenerative medicine market:
- In 2021, a new PhD program in regenerative medicine has been introduced by the Indiana University School of Medicine. The new PhD program will educate the leaders of tomorrow, adding to the nation's and Indiana's need for highly qualified labor. Through the development of fresh industry leaders, the program is anticipated to have a significant economic effect.
- In 2021, Sales of products for regenerative medicine that are illegal must end, says FDA. The Food and Drug Administration has promised to vigorously enforce regulations that producers of therapies for regenerative medicine—means to restore or replace harmed cells, tissues, and organs—must follow.
- On 2nd June, 2022, to advance the treatment of incurable diseases, a global stem cell research alliance is established. With the help of their combined expertise in stem cell disease modeling for drug development, cellular therapies for tissue regeneration, and translational regenerative medicine, experts from all over the world will be brought together by the reNEW partnership between Australia's Murdoch Children's Hospital, Denmark's University of Copenhagen, and the Netherlands' Leiden University Medical Center.
According to the study, key players dominating the global regenerative medicine market are American CryStem Corp (U.S), Amgen (U.S), Astellas Pharma (Japan), Abbott Laboratories (U.S), AstraZeneca (U.K), Avita Medical (U.K), Baxter International (U.S), Bayer AG (Germany), Bristol Myers Squibb (U.S), Integra Lifesciences (U.S), Medtronic (U.S), Nuvasive Inc (U.S), Pfizer (U.S), Styker Corporation (U.S), Smith and Nephew (U.K), Takara Holdings (Japan), Tissue Regenix (U.K), among others.
Browse the full report at https://www.sheeranalyticsandinsights.com/market-report-research/regenerative-medicine-market-21
The Global Regenerative Medicine Market Has Been Segmented Into:
The Global Regenerative Medicine Market – by Product Type:
- Therapeutics
- Banks
- Tools
- Services
The Global Regenerative Medicine Market – by Application Type:
- Oncology
- Musculoskeletal
- Wound Care
- Dental
- Cardiovascular
- Ophthalmology
- Others
The Global Regenerative Medicine Market – by Regions:
- North America
- The U.S.
- Canada
- Mexico
- Europe
- U.K.
- France
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- India
- China
- Japan
- Australia
- Rest of Asia Pacific
- LAMEA
- Middle East
- Saudi Arabia
- UAE
- Others
- Latin America
- Brazil
- Chile
- Others
- Africa
- South Africa
- Egypt
- Others
No comments:
Post a Comment